IDEXX Laboratories Inc. (IDXX)

IDEXX Laboratories Inc. (IDXX $629.35)
- $629.35 P/E (TTM): 49.91X Cap: $50.25B
- View IDXX Profile
- View Questions on IDXX

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Intuitive Surgical Inc. (ISRG $485.84)
- $485.84 P/E (TTM): 61.73X Cap: $172.53B
- View ISRG Profile
- View Questions on ISRG
Vertex Pharmaceuticals Incorporated (VRTX $491.47)
- $491.47 P/E (TTM): 34.37X Cap: $124.69B
- View VRTX Profile
- View Questions on VRTX
AbbVie Inc. (ABBV $231.50)
- $231.50 P/E (TTM): 176.72X Cap: $409.14B
- View ABBV Profile
- View Questions on ABBV
Johnson & Johnson (JNJ $243.45)
- $243.45 P/E (TTM): 22.07X Cap: $586.68B
- View JNJ Profile
- View Questions on JNJ
Eli Lilly and Company (LLY $1,040.00)
- $1,040.00 P/E (TTM): 45.32X Cap: $981.09B
- View LLY Profile
- View Questions on LLY
Merck & Company Inc. (MRK $121.41)
- $121.41 P/E (TTM): 16.05X Cap: $301.34B
- View MRK Profile
- View Questions on MRK
iShares Biotechnology ETF (IBB $172.50)
- $172.50 P/E (TTM): 20.63X Cap: $8.41B
- View IBB Profile
- View Questions on IBB
IDEXX Laboratories Inc. (IDXX $629.35)
- $629.35 P/E (TTM): 49.91X Cap: $50.25B
- View IDXX Profile
- View Questions on IDXX
Halozyme Therapeutics Inc. (HALO $79.44)
- $79.44 P/E (TTM): 16.72X Cap: $9.34B
- View HALO Profile
- View Questions on HALO
Incyte Corporation (INCY $101.10)
- $101.10 P/E (TTM): 15.77X Cap: $20.12B
- View INCY Profile
- View Questions on INCY
Catalyst Pharmaceuticals Inc. (CPRX $24.33)
- $24.33 P/E (TTM): 14.15X Cap: $2.99B
- View CPRX Profile
- View Questions on CPRX
Gilead Sciences CDR (CAD Hedged) (GILD $31.80)
- $31.80 P/E (TTM): 407.84X Cap: $263.07B
- View GILD Profile
- View Questions on GILD

Q: We have accumulated 11 healthcare stocks and 1 ETF, While LLY and ISRG are at half positions the rest are at initial 25% positions. Please advise [help!] us get to a more concentrated portfolio with a 3+ year horizon for reasonable opportunities in healthcare

Read Answer Asked by sam on January 13, 2026

Adobe Inc. (ADBE $263.97)
- $263.97 P/E (TTM): 15.81X Cap: $108.35B
- View ADBE Profile
- View Questions on ADBE
Accenture plc Class A (Ireland) (ACN $224.23)
- $224.23 P/E (TTM): 18.53X Cap: $148.08B
- View ACN Profile
- View Questions on ACN
Nike Inc. (NKE $63.13)
- $63.13 P/E (TTM): 37.14X Cap: $93.45B
- View NKE Profile
- View Questions on NKE
Thermo Fisher Scientific Inc (TMO $504.82)
- $504.82 P/E (TTM): 29.16X Cap: $189.66B
- View TMO Profile
- View Questions on TMO
TELUS Corporation (T $18.35)
- $18.35 P/E (TTM): 23.83X Cap: $28.40B
- View T Profile
- View Questions on T
IDEXX Laboratories Inc. (IDXX $629.35)
- $629.35 P/E (TTM): 49.91X Cap: $50.25B
- View IDXX Profile
- View Questions on IDXX

Q: Dear 5i,

I have a diverse portfolio with stocks and ETFs. Most of my portfolio is doing well. Want to know your thoughts about a few of my holdings that are not doing so well - Adobe, Nike, Accenture, TMO, IDXX and Telus.

What are your thoughts? Should I replace these with a US ETF or hold on. Thanks for your valuable advice as always.

Read Answer Asked by Alka on November 26, 2025

IDEXX Laboratories Inc. (IDXX $629.35)
- $629.35 P/E (TTM): 49.91X Cap: $50.25B
- View IDXX Profile
- View Questions on IDXX

Q: I bought half a position in IDEXX about a month ago, they recently had about a 25% pop after their results. Would you be comfortable for me adding to my position here?

Read Answer Asked by Andrew on August 11, 2025